



Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller

La Jolla, California--(February 8, 2021) - Tryp Therapeutics (**CSE: TRYP**) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announces it has commenced a collaboration with Dr. Jennifer Miller of the University of Florida as the Principal Investigator for a clinical trial to treat the symptoms associated with eating disorders. Tryp and Dr. Miller have begun designing a Phase 2a open-label, exploratory clinical study utilizing TRP-8802 in patients suffering from rare and orphan over-eating disorders.

"There are currently no approved drugs and only limited options to treat patients with rare over-eating disorders," stated Dr. Miller. "I'm excited to work with the Tryp team to explore the use of psilocybin as a new paradigm to treat symptoms associated with this devastating medical disease."

"We are pleased to announce the involvement of Dr. Miller, a leading expert in treating patients with rare eating disorders, in the planning for a clinical trial evaluating the safety, pharmacokinetics and efficacy of TRP-8802," stated Jim Kuo, CEO. "Our team is excited about the opportunity to advance our PFN program in a new indication that represents an important advancement in patient care and a significant commercial opportunity for Tryp in rare eating disorders."

Dr. Miller is a Professor in the division of pediatric endocrinology at University of Florida. She received her M.D. and her M.S. in Clinical Investigation from the University of Florida. She further trained in pediatrics and pediatric endocrinology at the University of Florida. Dr. Miller specializes in the care and treatment of individuals with Prader-Willi syndrome and other genetic causes of early-onset excessive weight gain.

About Tryp Therapeutics:

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp's psilocybin-for-neuropsychiatric disorders, or PFN™, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp's lead PFN™ drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States; and, rare over-eating disorders.

In addition to its PFN™ Program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft tissue sarcoma. Soft tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for Orphan Drug status.

Contact:

For inquiries, please contact us at:

TRYP Investor Relations

T: 1-833-811-TRYP (8797)

E: investors@trypterapeutics.com

Forward-Looking Information

Certain information in this news release, may contain forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of the Prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.